Exploratory/Developmental Bioengineering Research Grants...
Federal opportunity from Public Agency. Place of performance: United States.
- Source
- Open on official portal →
- Solicitation
- 0J8wzn8VMhixRVjFIm4H
- Performance
- United States
- Response
- No due date posted
Point of Contact
Agency & Office
Applicable wage determinations
Best public WD match for the notice location and scope.
Description
The National Cancer Institute (NCI) is seeking applications for Exploratory/Developmental Bioengineering Research Grants (EBRG) to demonstrate the feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.
* The grant is available for a wide range of applicant types, including special distr... | Title: Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional), Agency: U.S. National Institutes of Health, State: United States of America, Open Date: 1/11/2022, Close Date: 1/7/2028, Last Updated Date: 3/5/2026
Pricing and bid posture
Contractor-side estimate from visible notice metadata, NAICS/PSC, contract type, schedule hints, and BidPulsar workpaper assumptions. Not an IGCE, incumbent price, award value, or government budget.
This advisory bid range is visible page text for contractors and search engines: it summarizes the modeled floor, target, and premium bid posture for this solicitation.
Market snapshot
Baseline awarded-market signal across all contracting (sample of 400 recent awards; refreshed periodically).
Files
Files size/type shown when available.
BidPulsar Analysis
A practical, capture-style breakdown of fit, requirements, risks, and next steps.
Service match
Optional support routes matched to this notice after the core solicitation details.
Related hubs & trends
Navigate the lattice: hubs for browsing, trends for pricing signals.